POLE and colorectal carcinoma: Since it was revealed using our clinical cohort that some MSS patients may be TMB-H as a result of POLE mutations and this information could potentially expand the population of CRC who may benefit from ICIs, we sought to validate this notion by interrogating the MSI, TMB and RNAseq data of 533 CRC patients obtained from the TCGA database.